➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
AstraZeneca
Merck
Express Scripts
Baxter

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,535,717

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,535,717 protect, and when does it expire?

Patent 8,535,717 protects ELEPSIA XR and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 8,535,717
Title:Pharmaceutical composition
Abstract: The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising: (a) a highly soluble high dose active ingredient consisting essentially of therapeutically effective amount of levetiracetam or a pharmaceutically acceptable derivative thereof, and (b) a rate controlling means comprising a rate-controlling agent and/or a coating selected from (i) a active ingredient permeable coating surrounding the unit dosage form, and (ii) an active ingredient impermeable coating covering one or more surfaces but not all the surfaces of the unit dosage form, wherein the composition is in the form of a compact tablet and the levetiracetam or a pharmaceutically acceptable derivative thereof is present in an amount ranging from about 55% to about 90% by weight of the tablet.
Inventor(s): Zala; Yashoraj Rupsinh (Mumbai, IN), Dharmadhikari; Nitin Bhalachandra (Mumbai, IN)
Assignee: Sun Pharma Advanced Research Company Limited (Mumbai, IN)
Application Number:13/102,328
Patent Claim Types:
see list of patent claims
Dosage form; Composition;

Drugs Protected by US Patent 8,535,717

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-002 Dec 20, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,535,717

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
India196/MUM/2005Feb 22, 2005

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Express Scripts
Johnson and Johnson
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.